Skip to content

Study · Animal study (in vivo) · rat · 1986

8 results

[Catecholaminergic component of the action of a heptapeptide analog of ACTH4-10 on the open-field behavior of rats].

Antonova LV, Kamenskiĭ AA, Vlasova TI, Sarycheva NIu, Nezavibat'ko VN

Biulleten' eksperimental'noi biologii i meditsiny1 Nov 1986

PMID3022845 (opens in a new tab)PepBankPUB-03022845
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the heptapeptide at 0.015 mg/kg did not change open field behaviour in the first test series.

    In plain wordsIn rats, the heptapeptide at 0.015 mg/kg did not change open field behaviour in the first test.

    Peptide
    Semax
    Outcome
    No significant changeOpen field behaviour in the first test series
    Study

    ratn: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.015 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the heptapeptide abolished amphetamine-induced stimulation of exploratory behaviour.

    In plain wordsIn rats, the heptapeptide removed the extra exploring caused by amphetamine.

    Peptide
    Semax
    Outcome
    DecreaseAmphetamine-induced exploratory behaviour
    Study

    ratn: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptide abolished amphetamine-induced stimulation of the exploratory and grooming behaviour.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the heptapeptide abolished amphetamine-induced stimulation of grooming behaviour.

    In plain wordsIn rats, the heptapeptide removed the extra grooming caused by amphetamine.

    Peptide
    Semax
    Outcome
    DecreaseAmphetamine-induced grooming behaviour
    Study

    ratn: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptide abolished amphetamine-induced stimulation of the exploratory and grooming behaviour.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given haloperidol or apomorphine, the heptapeptide tended to normalise the disturbed extinction of exploratory behaviour.

    In plain wordsIn rats given haloperidol or apomorphine, the heptapeptide tended to bring back normal fading of exploring.

    Peptide
    Semax
    Outcome
    IncreaseExtinction of exploratory behaviour after haloperidol or apomorphine
    Study

    ratn: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When the peptide was administered with haloperidol or apomorphine, the extinction tended to become normal.
    2 context sentences
    Summary · context
    Extinction of the rats' exploratory behaviour during second test series in the open field (7 days later) was disturbed when haloperidol or apomorphine were injected before the first test series.
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, the heptapeptide did not change noradrenaline content in the forebrain.

    In plain wordsIn rats, the heptapeptide did not change forebrain noradrenaline content.

    Peptide
    Semax
    Outcome
    No significant changeForebrain noradrenaline content
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heptapeptide failed to change noradrenaline, dopamine or 5-hydroxytryptamine content in the rat forebrain.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats, the heptapeptide did not change dopamine content in the forebrain.

    In plain wordsIn rats, the heptapeptide did not change forebrain dopamine content.

    Peptide
    Semax
    Outcome
    No significant changeForebrain dopamine content
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heptapeptide failed to change noradrenaline, dopamine or 5-hydroxytryptamine content in the rat forebrain.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats, the heptapeptide did not change 5-hydroxytryptamine content in the forebrain.

    In plain wordsIn rats, the heptapeptide did not change forebrain 5-hydroxytryptamine content.

    Peptide
    Semax
    Outcome
    No significant changeForebrain 5-hydroxytryptamine content
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Heptapeptide failed to change noradrenaline, dopamine or 5-hydroxytryptamine content in the rat forebrain.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.
  8. 08LabEx vivo tissueMechanism

    In rat striatal and hypothalamic synaptosomes, the heptapeptide at 10(-4) M moderately reduced tyrosine hydroxylation velocity, depending on tyrosine concentration.

    In plain wordsIn lab tests on rat brain nerve-ending preparations, the heptapeptide moderately slowed tyrosine hydroxylation.

    Peptide
    Semax
    Outcome
    DecreaseTyrosine hydroxylation velocity in synaptosomes
    Study

    ratn: not reported in source

    Rat striatal or hypothalamic synaptosomes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10(-4) MAs given in this study (rat).

    Source sentences

    Summary
    However, this peptide at a concentration of 10(-4) M moderately diminished tyrosine hydroxylation velocity in the rat striatal or hypothalamic synaptosomes, the effect depending on tyrosine concentration.
    1 context sentence
    Summary · context
    Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH4-10 analog) at a dose of 0.015 mg/kg failed to alter open field behaviour of rats in the first test series.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.